ISSN:
1437-7780
Keywords:
Key wordsHelicobacter pylori
;
β-Lactamase inhibitor
;
Amoxicillin
;
Clarithromycin
;
Azithromycin
;
Antibacterial activity
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Recently, it was reported that amoxicillin-clavulanate has slightly higher activity than amoxicillin against Helicobacter pylori. In this study, we evaluated the in-vitro antibacterial activity of β-lactamase inhibitors against H. pylori. We investigated the susceptibility of 30 H. pylori strains to β-lactamase inhibitors, including clavulanate, sulbactam, and tazobactam. In short-term bactericidal studies, a clinical isolate of H. pylori NU27 was exposed to 1 × minimum inhibitory concentration (MIC) of the β-lactamase inhibitors, amoxicillin, clarithromycin, and amoxicillin-clavulanate for 3 and 6 h. The MICs90 for these β-lactamase inhibitors were 2, 4, and 2 mg/l, respectively. The short-term bactericidal studies showed that these β-lactamase inhibitors decreased viable counts of H. pylori during 6-h exposure at 1 × MIC. Our results suggest that β-lactamase inhibitors have in-vitro antibacterial activity against H. pylori. Amoxicillin and clavulanate used in combination resulted in increased antibacterial activity.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s101560050036
Permalink
